19 results
425
EX-10.1
CRVO
CervoMed Inc
19 May 23
Business combination disclosure
4:31pm
on the Separation Date. All benefits and perquisites of employment are ceased as of the Separation Date, except that you will receive, to the extent
8-K
EX-10.1
CRVO
CervoMed Inc
19 May 23
Entry into a Material Definitive Agreement
4:31pm
on the Separation Date. All benefits and perquisites of employment are ceased as of the Separation Date, except that you will receive, to the extent
DEFC14A
CRVO
CervoMed Inc
5 Dec 22
Proxy in contested solicitation
5:12pm
-term incentive compensation, special or supplemental benefits or perquisites and any and all other compensation applicable to our Chief Executive Officer
PRER14A
l6v9h5iuazh6f
28 Nov 22
Preliminary revised proxy
5:17pm
PREC14A
hbxf 6k8jut3y
18 Nov 22
Preliminary proxy with contested solicitation
5:08pm
8-K
EX-10.1
v64amqul0l
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
- Prev
- 1
- Next